Chimeric VEGF-A Polypeptides for Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for promoting angiogenesis lack effectiveness and specificity, particularly in modulating processes such as angiogenesis, lymphangiogenesis, and wound healing, with existing growth factors showing limited control over receptor activation and activity.
Innovation Solution
Development of recombinant polynucleotides and polypeptides from the VEGF PDGF family with modified flanking sequences, including chimeric constructs with RTK binding domains, heterologous flanking domains, and linkages that connect these domains to receptor tyrosine kinases, allowing for agonist or antagonist activity by binding to VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, and PDGFR-beta receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing growth factors are used to promote angiogenesis, then some angiogenic activity is achieved, but the effectiveness and specificity are limited
Solution Approach 1:
The growth factor molecule is divided into distinct functional domains: an RTK binding domain for receptor interaction and heterologous flanking domains for additional functionality. This segmentation allows independent optimization of binding affinity and specificity for different receptors, improving both effectiveness and specificity of angiogenesis promotion
Solution Approach 2:
Chimeric growth factor constructs are created by combining the RTK binding domain of one growth factor with flanking domains from other growth factors or proteins. This composite structure integrates multiple functional properties into a single molecule, enhancing angiogenic effectiveness while providing specificity through selective domain combinations
2Adaptability or versatility
If growth factors are designed to bind multiple receptors, then versatility is improved, but control over receptor activation is reduced
Solution Approach 1:
Different domains within the chimeric growth factor are assigned specific functional qualities: the RTK binding domain provides selective receptor binding capability while heterologous flanking domains provide localized functions such as dimerization or stabilization. This local quality assignment maintains control over which receptors are activated while preserving versatility
3Reliability
If flanking sequences are added to growth factors, then angiogenic properties are enhanced, but molecular complexity increases
Solution Approach 1:
The enhanced growth factor is segmented into modular domains that can be independently characterized and optimized. The RTK binding domain and flanking domains are distinct functional units that can be separately engineered, which manages molecular complexity through systematic modularity while achieving enhanced angiogenic properties
Solution Approach 2:
The heterologous flanking domains are designed to perform multiple functions simultaneously, such as promoting dimerization, stabilizing the active conformation, and enhancing receptor binding affinity. This multi-functionality reduces the need for additional separate components, managing overall molecular complexity while improving angiogenic effectiveness
Data Source
AI summary
The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-2 ligand. The chimeric molecules of the present invention retain VEGFR-2 binding activity and an enhanced angiogenic activity as compared to native VEGF-A.